Multiple Mechanisms of Lung Surfactant Inhibition

@article{Holm1999MultipleMO,
  title={Multiple Mechanisms of Lung Surfactant Inhibition},
  author={Bruce A. Holm and Zhengdong Wang and Robert H. Notter},
  journal={Pediatric Research},
  year={1999},
  volume={46},
  pages={85-93}
}
We studied the mechanisms by which C16:0 lysophosphatidylcholine (LPC) and albumin inhibit the surface activity of calf lung surfactant extract (CLSE) by using a pulsating bubble apparatus with a specialized hypophase exchange system, plus adsorption and Wilhelmy balance measurements. In the absence of inhibitors, CLSE (1 mg phospholipid/mL) reached minimum surface tension (γmin) < 1 mN/m within 5 min of bubble pulsation at 20 cycles/min at 37°C. Mixtures of CLSE:LPC had impaired surface… Expand
Surface activity of a synthetic lung surfactant containing a phospholipase-resistant phosphonolipid analog of dipalmitoyl phosphatidylcholine.
  • Z. Wang, A. Schwan, +5 authors R. Notter
  • Chemistry, Medicine
  • American journal of physiology. Lung cellular and molecular physiology
  • 2003
TLDR
Findings indicate that synthetic surfactants containing DEPN-8 combined with surfactant proteins or related synthetic peptides have potential utility for treating Surfactant dysfunction in inflammatory lung injury. Expand
Activity and inhibition resistance of a phospholipase-resistant synthetic surfactant in rat lungs.
TLDR
The results support the potential of developing highly active and inhibition-resistant synthetic exogenous surfactants containing DEPN-8 + apoprotein/peptide constituents for use in treating direct pulmonary forms of clinical acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS). Expand
Inhibition of surfactant activity by Pneumocystis carinii organisms and components in vitro.
  • Z. Wang, A. Foye, +5 authors R. Notter
  • Biology, Medicine
  • American journal of physiology. Lung cellular and molecular physiology
  • 2005
TLDR
Results indicate that in addition to surfactant dysfunction induced by inflammatory lung injury and edema-derived inhibitors in Pc pneumonia, disrupted Pc organisms in the alveolar lumen also have the potential to directly inhibit endogenous and exogenous lung surfactants in affected patients. Expand
Peripheral cell wall lipids of Mycobacterium tuberculosis are inhibitory to surfactant function.
TLDR
It is found that TB contains multiple lipids that can directly impair the biophysical function of endogenous and exogenous lung surfactants and could worsen surfactant dysfunction caused by plasma proteins or other endogenous substances induced by inflammatory injury in the infected lungs. Expand
A comparative study of mechanisms of surfactant inhibition.
TLDR
The results suggest that in ARDS, competitive adsorption may not sufficiently explain high surface tension, and that disruption of the surfactant film needs to be given causal consideration. Expand
An albumin-associated PLA2-like activity inactivates surfactant phosphatidylcholine secreted from fetal type II pneumocytes.
  • J. E. Damas, M. Cake
  • Chemistry, Medicine
  • American journal of physiology. Lung cellular and molecular physiology
  • 2011
TLDR
This study has shown that, when cultured type II pneumocytes are exposed to lipoprotein-free serum (LFS), the level of lyso-phosphatidylcholine (lyso-PC) in the secreted surfactant phospholipids is markedly elevated with a concomitant decline in the level in the media. Expand
Activity and biophysical inhibition resistance of a novel synthetic lung surfactant containing Super-Mini-B DATK peptide
TLDR
Synthetic surfactants containing S-MB DATK (or related peptides) combined with lipids appear to have significant future potential for treating clinical states of surfactant deficiency or dysfunction, such as neonatal and acute respiratory distress syndromes. Expand
Inactivation of Pulmonary Surfactant by Lysophosphatidylcholine
ABSTRACT The aim of the study is to examine the influence of the lysophosphatidylcholine (lysoPC) to surface properties of INFASURF, a replacement lung surfactant, using the methods of thin foamExpand
Lysophospholipid and fatty acid inhibition of pulmonary surfactant: non-enzymatic models of phospholipase A2 surfactant hydrolysis.
TLDR
Generation of lysophospholipids is the principal mechanism of phospholipase-mediated surfactant injury in non-enzymatic models and these models and findings will assist in understanding more complex in vitro and in vivo studies of phosphorus-mediated Surfactant Injury. Expand
Inhibition and counterinhibition of Surfacen, a clinical lung surfactant of natural origin
TLDR
Under physiologically-mimicking conditions, a cholesterol-free clinical surfactant such as Surfacen is less susceptible to inhibition by cholesterol-mobilizing environments than cholesterol-containing natural surfactants, as a consequence of a markedly reduced susceptibility to incorporation of exogenous cholesterol. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 49 REFERENCES
Additivity of protein and nonprotein inhibitors of lung surfactant activity.
  • Z. Wang, R. Notter
  • Medicine
  • American journal of respiratory and critical care medicine
  • 1998
TLDR
Results indicate that surfactant dysfunction in acute respiratory distress syndrome (ARDS) could be increased in severity by interactions between some inhibitory substances, but that supplementation with exogenous CLSE would be effective in reversing inactivation by the mixtures of blood proteins, membrane lipids, and fatty acids studied. Expand
Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity.
TLDR
Data show that molecular components in hemorrhagic pulmonary edema can biophysically inactivate endogenous LS and adversely affect lung mechanics, and exogenous surfactant replacement can reverse this process even in the continued presence of inhibitor molecules and thus has potential utility in therapy for adult as well as neonatal RDS. Expand
A biophysical mechanism by which plasma proteins inhibit lung surfactant activity.
TLDR
The data suggest that some proteins may inhibit surfactant function by preventing the surfactants phospholipids from adsorbing to the air-liquid interface, possibly by a competition between the proteins and CLSE phospholIPids for space at theAir- liquid interface rather than direct molecular interactions between proteins and surfactan. Expand
Enhancement of biophysical activity of lung surfactant extracts and phospholipid-apoprotein mixtures by surfactant protein A.
TLDR
The finding that SP-A enhances the ability of CLSE and other surfactant mixtures containing SP-B to resist inhibition is an advantage that will need to be weighed against other factors such as increased antigenicity and heat sensitivity in therapeutic applications in surfactants replacement therapy. Expand
Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations.
TLDR
It is concluded that various natural surfactant extracts and an apoprotein-based synthetic Surfactant mixture markedly differ in their sensitivity to inhibitory plasma proteins. Expand
Biophysical inhibition of synthetic phospholipid-lung surfactant apoprotein admixtures by plasma proteins.
TLDR
The surface activity of synthetic phospholipid-apoprotein admixtures was decreased significantly by the plasma proteins albumin and fibrinogen, but with varying characteristics depending on the apoprotein preparation involved. Expand
Biophysical inhibition of synthetic lung surfactants.
TLDR
Results showed that several simple mixtures of dipalmitoyl phosphatidylcholine with fatty acids or diacylglycerols could be formulated to give good adsorption facility and dynamic surface tension lowering to less than 1 mN/m in pulsating bubble measurements at 37 degrees C. Expand
Inhibition of pulmonary surfactant function by phospholipases.
Previous studies have shown that respiratory failure associated with disorders such as acute pancreatitis correlates well with increased levels of phospholipase A2 (PLA2) in lung lavages and thatExpand
Inhibition of pulmonary surfactant by oleic acid: mechanisms and characteristics.
TLDR
Findings suggested that OA inhibited pulmonary surfactant activity by disrupting the rigid interfacial film responsible for the generation of very low surface tension during dynamic compression. Expand
Artificial pulmonary surfactant inhibited by proteins.
TLDR
It is concluded that proteins present in the airways may seriously interfere with the activity of Surfactant TA. Expand
...
1
2
3
4
5
...